Djordje Marina

Mr. Djordje Marina


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
DMDjordje Marina
Djordje Marina
PBPia Burman
Pia Burman
MKMarianne Klose
Marianne Klose
OCOlivera Casar-Borota
Olivera Casar-Borota
Raul LuqueRaul Luque
Raul Luque
UFUlla Feldt-Rasmussen
Ulla Feldt-Rasmussen

24 June 2022 in Cancer Medicine
Verified
Journal Article
Open access
DMDjordje Marina
Djordje Marina
ÅRÅse Krogh Rasmussen
Åse Krogh Rasmussen
KBKristian Buch‐Larsen
Kristian Buch‐Larsen
LGLinn Gillberg
Linn Gillberg
MAMichael Andersson
Michael Andersson
PSPeter Schwarz
Peter Schwarz
Introduction: Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti‐oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented. While the most common side‐effects of this therapy are well‐defined, less is known about its effects on thyroid function. In women treated for early BC, an average of 1–5 kg weight gain has been observed after treatment with chemotherapy/anti‐oestrogens. We aim to evaluate the current knowledge on the side effects of tamoxifen and letrozole treatments on thyroid function, followed by its potential influence on the observed weight gain.Methods: We searched PubMed and found 16 publications on thyroid function and tamoxifen treatment in pre‐ and post‐menopausal women with early‐ and advanced BC, whereas five publications on letrozole treatment in post‐menopausal women with advanced BC.Results: According to the current literature, there is an overall tendency towards a mild and transient thyroid dysfunction, that is, subclinical hypothyroidism in tamoxifen‐treated patients. Only one publication reported further significant changes in thyroid hormones beyond one year of tamoxifen treatment. No significant changes in thyroid function have been observed among letrozole‐treated patients.Conclusion: Tamoxifen‐treated patients can develop mild and transient thyroid dysfunction within the first 12 months, yet further significant changes in thyroid function beyond one year of tamoxifen treatment have been reported in a single study. There is no evidence of thyroid dysfunction in letrozole‐treated patients. Current literature does not focus on subclinical hypothyroidism as a possible cause of weight gain in patients with BC. Subgrouping of BC patients and studies with a longer observation of thyroid hormones and weight changes during and after anti‐oestrogen treatment are needed to further elucidate how anti‐oestrogens affect thyroid function.

1 January 2009 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
NKNada Kostic
Nada Kostic
ZCZorica Caparevic
Zorica Caparevic
DMDjordje Marina
Djordje Marina
SISanja Ilic
Sanja Ilic
JRJana Radojkovic
Jana Radojkovic
VBVera Bakic-Celic
Vera Bakic-Celic
Background/Aim. Exercise is a well recognized model of oxidative stress and, also, an important tool in diabetes management. The aim of our study was to evaluate oxidative stress in patients with diabetes mellitus type 2 and to determine influence of acute exercise training on the investigated parameters. Methods. To evaluate oxidative stress in the patients, we determinated following parameters: triglycerides (TG), total cholesterol, low density lipoprotein cholesterol (LDL), oxidized LDL cholesterol (Ox LDL), superoxide dismutase (SOD), glutathione peroxidase (GSHPx), plasminogen activator inhibitor (PAI) which were measured at rest and immediately after the acute bout of cardiopulmonary exercise cycle-ergometer test. Results. In basal condition, diabetic patients compared to controls have significant higher values of TG (3.12 ? 1.09 vs 1.74 ? 0.9 mmol/L, p < 0.01), Ox LDL (84.73 ? 16.90 vs 79.00 ? 29.26 mmol/L, p < 0.05) and SOD enzyme activity (913.38 ? 120.36 vs 877.14 ? 153.18 U/g Hb, p < 0.05). During the acute exercise test, there was significant increase of Ox LDL in both the study patients (from 84.73 ? 16.90 to 92.33 ? 23.29 mmol/L, p < 0.05) and in the control group (from 79.00 ? 29.26 to 89.30 ? 29.07 mmol/L, p < 0.05). SOD activity was significantly increased in both groups during exercise, in diabetic patients from 913.38 ? 120.36 to 921.50 ? 130.03 U/gHb, p < 0.05, and in the controls from 877.14 ? 153.18 to 895.00 ? 193.49, U/gHb, p < 0.05. GSH-Px activity was significantly increased only in the diabetic patients after the acute exercise (from 45.04 ? 11.19 to 51.81 ? 15.07 U/gHb, p < 0.01), but not in the controls (from 44.63 ? 13.73 to 43.97 ? 25.97 U/gHb, p = ns). PAI significantly decreased during the exercise test, only in the healthy subjects (from 2.60 ? 0.35 to 2.22 ? 0.65, p < 0.05). Type 2 diabetic patients with complications had only significant increase in GSH-Px activity (from 47.10 ? 7.37 to 54.52 ? 11.97 U/gHb, p < 0.01). Conclusion. Elevated Ox LDL, SOD and GSH-Px levels are associated with acute exercise in type 2 diabetic patients. We suggest that it could be a compensatory mechanism to preventing free radicals tissue damage. We hypothesize that a physical training program induces an enhance of muscular and liver antioxidant enzymes activity and reduces oxidative stress. Further studies are needed to explore the relationship between exercise and antioxidant system in diabetic patients with and without complications.

13 July 2023 in Cancer Medicine
Verified
Journal Article
Open access
ICIda Bager Christensen
Ida Bager Christensen
MAMarie‐Louise Abrahamsen
Marie‐Louise Abrahamsen
LRLucas Ribas
Lucas Ribas
KBKristian Buch‐Larsen
Kristian Buch‐Larsen
DMDjordje Marina
Djordje Marina
LGLinn Gillberg
Linn Gillberg
Background: Adjuvant chemo‐ and radiotherapy cause cellular damage to tumorous and healthy dividing cells. Chemotherapy has been shown to cause mitochondrial respiratory dysfunction in non‐tumorous tissues, but the effects on human peripheral blood mononuclear cells (PBMCs) remain unknown.Aim: We aimed to investigate mitochondrial respiration of PBMCs before and after adjuvant chemo‐ and radiotherapy in postmenopausal patients with early breast cancer (EBC) and relate these to metabolic parameters of the patients.Methods: Twenty‐three postmenopausal women diagnosed with EBC were examined before and shortly after chemotherapy with (n = 18) or without (n = 5) radiotherapy. Respiration (O2 flux per million PBMCs) was assessed by high‐resolution respirometry of intact and permeabilized PBMCs. Clinical metabolic characteristics and mitochondrial DNA (mtDNA) content of PBMCs (mtDN relative to nuclear DNA) were furthermore assessed.Results: Respiration of intact and permeabilized PBMCs from EBC patients significantly increased with adjuvant chemo‐ and radiotherapy (p = 6 × 10−5 and p = 1 × 10−7, respectively). The oxygen flux attributed to specific mitochondrial complexes and respiratory states increased by 17–43% compared to before therapy initiation. Similarly, PBMC mtDNA content increased by 40% (p = 0.002). Leukocytes (p = 0.0001), hemoglobin (p = 0.0003), and HDL cholesterol (p = 0.003) concentrations decreased whereas triglyceride (p = 0.01) and LDL (p = 0.02) concentrations increased after treatment suggesting a worsened metabolic state. None of the metabolic parameters or the mtDNA content of PBMCs correlated significantly with PBMC respiration.Conclusion: This study shows that mitochondrial respiration and mtDNA content in circulating PBMCs increase after adjuvant chemo‐ and radiotherapy in postmenopausal patients with EBC. Besides the increased mtDNA content, a shift in PBMC subpopulation proportions towards cells relying on oxidative phosphorylation, who may be less sensitive to chemotherapy, might influence the increased mitochondrial respiration observed iafter chemotherapy.

19 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Antonino CatalanoAntonino Catalano
Antonino Catalano
COCecilia Oliveri
Cecilia Oliveri
GNGiuseppe Natale
Giuseppe Natale
RARita Maria Agostino
Rita Maria Agostino
Giovanni SquadritoGiovanni Squadrito
Giovanni Squadrito
Domenico SantoroDomenico Santoro
Domenico Santoro
Background/Objectives: Renal function influences bone metabolism, as kidney failure can increase the risk of fractures. Denosumab is an approved osteoporosis treatment, but its efficacy in relation to renal function has not yet been studied in real-life scenarios. This study aimed to investigate the denosumab-induced change in bone mineral density (BMD) according to kidney function. Methods: A retrospective analysis was conducted at the outpatient clinic in postmenopausal women receiving denosumab (60 mg subcutaneously administered every 6 months). The glomerular filtration rate (eGFR) was measured by the 2021 CKD-EPI equation and patients were stratified for eGFR categories. BMD was measured by dual-energy X-ray absorptiometry. Results: 128 women (mean age 70.3 ± 9.4 years) were recruited. The mean denosumab treatment duration was 3.9 ± 1.4 years and all the participants had improved BMD values. In stepwise multiple regression analysis—after controlling for age, BMI, and treatment duration—the eGFR value (ß = −0.11, SE 0.04, p = 0.01) was independently associated with the lumbar spine BMD change. The same association remained when the eGFR categories were considered (ß = 3.564, SE 1.29, p = 0.007). In addition, after controlling for BMI and the duration of denosumab treatment, age (ß = −0.7915, SE 0.37, p = 0.03) and eGFR (ß = −0.3257, SE 0.1567, p = 0.04) were found to be associated with femoral neck BMD change. The association remained when considering eGFR categories (ß = 8.7339, SE 4.29, p = 0.04). Conclusions: This retrospective study suggests that eGFR is associated with denosumab efficacy in postmenopausal women treated for osteoporosis.

6 August 2024 in Cancer Medicine
Verified
Journal Article
Open access
DMDjordje Marina
Djordje Marina
KBKristian Buch‐Larsen
Kristian Buch‐Larsen
LGLinn Gillberg
Linn Gillberg
MAMads Albrecht Andersen
Mads Albrecht Andersen
MAMichael Andersson
Michael Andersson
PSPeter Schwarz
Peter Schwarz
Objective: Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer (EBC). Among others, weight gain is one of the observed side effects of both chemotherapy and other cancer treatments; however, the mechanism is not well‐described. In this study, we aimed to assess thyroid function before and shortly after the course of chemotherapy for EBC.Methods: This is a prospective cohort study of women diagnosed with EBC. The main outcome was the thyroid function and body weight before and after completing chemotherapy. Secondary outcomes were the presence of thyroid autoantibodies and treatment radiation dosage. We included 72 patients treated with adjuvant chemotherapy, whereas 59 patients also received supraclavicular locoregional radiotherapy. Triple‐negative breast cancer (BC) patients receiving chemoimmunotherapy were excluded.Results: After the chemotherapy, we observed an increase in thyroid‐stimulating hormone (p = 0.03) and a decrease in free‐thyroxine (p = 0.0006), with no significant weight change. The prevalence of autoimmune thyroiditis was low. On average 3 months post‐chemo, we found no statistically significant difference in the thyroid function of women treated versus not treated with supraclavicular locoregional radiotherapy.Conclusions: Although statistically significant changes in thyroid hormones were observed, this study suggests no obvious clinically significant changes in thyroid function in women with early BC after the course of chemotherapy. The decrease in thyroid function was not related to autoimmunity, non‐thyroidal illness, radiotherapy, or high‐dose corticosteroids. Further studies with a longer follow‐up of thyroid function after adjuvant chemotherapy and supraclavicular locoregional radiotherapy are needed.